This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Poster presentation

Safety and efficacy of lopinavir/ritonavir compared to nelfinavir-based HAART during pregnancy

JM Peña¹, MI González², JF Pascual-Pareja³, J López-Aldeguer⁴, JA Iribarren⁵, M Leyes⁶, P Miralles⁷, J Sanz⁸, A Ocampo⁹, JL Gómez-Sirvent¹⁰ and JT Ramos¹¹

¹  La Paz, Madrid, Spain

²  Doce de Octubre, Madrid, Spain

³  Hospital Universitario La Paz, Madrid, Spain

⁴  La Fe, Valencia, Spain

⁵  Donosti, San Sebastian, Spain

⁶  Son Dureta, Mallorca, Spain

⁷  Gregorio Marañón, Madrid, Spain

⁸  Principe de Asturias, Alcálá de Henares, Spain

⁹  Xeral Cies, Vigo, Spain

¹⁰  Tenerife, Tenerife, Spain

¹¹  Getafe, Getafe, Spain

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):P221doi:10.1186/1758-2652-11-S1-P221

The electronic version of this abstract is the complete one and can be found online at: http://www.jiasociety.org/content/11/S1/P221

Published:

10 November 2008

© 2008 Peña et al; licensee BioMed Central Ltd.

Purpose of the study

To compare the safety and efficacy of lopinavir/ritonavir and nelfinavir-based regimens in HIV-1 infected pregnant women.

Methods

A prospective cohort study to evaluate HIV mother-to-child transmission. The study took place at 13 Spanish hospitals. We reviewed the records of all pregnant women treated with NFV (NCR) or LOP/r-containing (LOP/r CR) regimens during pregnancy from May 2001 to December 2007. Drug selection was up to the physician. Abnormalities were graded according to the National Institute of Allergy and Infectious Disease Division of AIDS toxicity guidelines. Data of mother and their children were recorded following a standard protocol.

Summary of results

355 mothers were enrolled: mean age 31 years; Caucasian 74%; HCV co-infection 34%; 13% were on C3 according to CDC category; heterosexual transmission 64%. 40% received antiretroviral therapy for the first time during pregnancy. 121 (34%) were on LOP/r CR and 234 (66%) on NCR. Baseline characteristics, side-effects and discontinuation of LPV or NFV of both groups are shown in Table 1 (values are expressed as the median [IQR] for continuous variables and as N [%] for categorical variables). No aminotransferases abnormalities (grade 3–4) or clinical hepatitis were observed. There were no differences in both groups according to weight and gestational age of the babies at delivery. There was a case of vertical transmission (a mother treated with NFV and viral load above 500,000 copies/ml).

Conclusion

In our cohort lopinavir/ritonavir and nelfinavir-based regimens during pregnancy were safe, effective and well tolerated.

Have something to say? Post a comment on this article!